Key facts

Invented name
Talzenna
Active Substance
talazoparib
Therapeutic area
Oncology
Decision number
P/130/2021
PIP number
EMEA-002066-PIP02-20
Pharmaceutical form(s)
  • Capsule (hard)
  • Capsule (soft)
Condition(s) / indication(s)
  • Treatment of breast malignant neoplasms
  • Treatment of prostate malignant neoplasms
Route(s) of administration
Oral use
Contact for public enquiries

Pfizer Europe MA EEIG

Tel. +44 (0)1304 646 607
E-mail: pip_enquiries@pfizer.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

P/0130/2021: EMA decision of 14 April 2021 on the granting of a product specific waiver for talazoparib (Talzenna), (EMEA-002066-PIP02-20)

How useful do you find this page?